C4 Therapeutics (CCCC) Non Operating Investment Income (2020 - 2025)
Historic Non Operating Investment Income for C4 Therapeutics (CCCC) over the last 6 years, with Q2 2025 value amounting to -$73000.0.
- C4 Therapeutics' Non Operating Investment Income fell 2166.67% to -$73000.0 in Q2 2025 from the same period last year, while for Jun 2025 it was $410000.0, marking a year-over-year decrease of 6926.54%. This contributed to the annual value of $180000.0 for FY2024, which is 9551.12% down from last year.
- According to the latest figures from Q2 2025, C4 Therapeutics' Non Operating Investment Income is -$73000.0, which was down 2166.67% from -$10000.0 recorded in Q1 2025.
- Over the past 5 years, C4 Therapeutics' Non Operating Investment Income peaked at $1.7 million during Q1 2023, and registered a low of -$2.9 million during Q1 2022.
- In the last 5 years, C4 Therapeutics' Non Operating Investment Income had a median value of -$66500.0 in 2024 and averaged -$2388.9.
- Over the last 5 years, C4 Therapeutics' Non Operating Investment Income had its largest YoY gain of 135000.0% in 2021, and its largest YoY loss of 1250000.0% in 2021.
- C4 Therapeutics' Non Operating Investment Income (Quarter) stood at -$620000.0 in 2021, then soared by 305.16% to $1.3 million in 2022, then tumbled by 38.92% to $777000.0 in 2023, then crashed by 151.74% to -$402000.0 in 2024, then soared by 81.84% to -$73000.0 in 2025.
- Its last three reported values are -$73000.0 in Q2 2025, -$10000.0 for Q1 2025, and -$402000.0 during Q4 2024.